Once p53 mutation or deletion occurs, the tumor inhibitory function of CLDN7 is lost, indicating that the tumor inhibitory effect of CLDN7 in colorectal cancer is closely related to the status of p53. Rodrigues et al. [46] have shown that 80% of patients with mantle cell lymphoma with tp53 mutations die within the first 5 years of diagnosis. Here, CLDN7 is linked to neoplasm.